| Title |
Ebrotidine
|
|---|---|
| Published in |
Drugs, October 2012
|
| DOI | 10.2165/00003495-199651060-00006 |
| Pubmed ID | |
| Authors |
Sanjay S. Patel, Michelle I. Wilde |
| Abstract |
Ebrotidine is the first of a new generation of H2 receptor antagonists with gastroprotective activity It stimulates epithelial cell proliferative activity and produces beneficial physicochemical changes in the gastric mucus that contribute to its gastro-protective action against ethanol-, aspirin- or stress-induced gastric mucosal damage The antisecretory properties of ebrotidine are similar to those of ranitidine and approximately 10-fold greater than those of cimetidine This drug exhibits anti-Helicobacter pylori activity that is synergistic with a number of antibacterial agents; it inhibits the urease enzyme and the proteolytic and mucolytic activities of H. pylori, and counteracts the inhibitory effects of H. pylori lipo-polysaccharide Ebrotidine is as effective as ranitidine for the treatment of patients with gastric or duodenal ulcers or erosive reflux oesophagitis Ebrotidine therapy results in significantly better ulcer healing rates than ranitidine treatment in patients who smoke. |
Mendeley readers
The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 13% |
| Unknown | 7 | 88% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 2 | 25% |
| Librarian | 1 | 13% |
| Other | 1 | 13% |
| Professor | 1 | 13% |
| Student > Doctoral Student | 1 | 13% |
| Other | 2 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 50% |
| Biochemistry, Genetics and Molecular Biology | 1 | 13% |
| Chemistry | 1 | 13% |
| Social Sciences | 1 | 13% |
| Unknown | 1 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 July 2021.
All research outputs
#8,534,976
of 25,373,627 outputs
Outputs from Drugs
#1,511
of 3,464 outputs
Outputs of similar age
#67,552
of 202,324 outputs
Outputs of similar age from Drugs
#662
of 1,807 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,464 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 202,324 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,807 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.